National Comprehensive Cancer Network

Educational Events & Programs

Policy Summit:
Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies

Friday, April 25, 2014
8:00 AM – 3:30 PM

Bethesda Marriott
Bethesda, MD

Overview

With cancers increasingly recognized as being comprised of many subtypes differentiated by specific molecular profiles, identifying the most effective combination therapies is challenging. Defining appropriate patient subsets, selecting agents active against specific targets, predicting effective therapeutic combinations and appropriately interpreting clinical trials results are significant problems for pharmaceutical companies, clinicians, statisticians and regulators which will need to be addressed in order to meet the needs of cancer patients.

NCCN will host a Policy Summit: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies, on April 25, 2014 at the Bethesda Marriott, 5151 Pooks Hill Rd., Bethesda, Maryland. Speakers will be selected from an NCCN working group on these challenges comprised of researchers, statisticians, regulators and payers along with other stakeholders to provide diverse perspectives.

The Summit is designed for multiple stakeholders including physicians, industry, government, patients and other interested parties. This Summit is open to the public

Click here to register.

If you have questions about NCCN Policy Summits, please contact Liz Danielson, Director, Payer & Employer Initiatives.

Agenda*:

8:00 – 9:00 AM
Breakfast and Registration

9:05 – 9:20 AM   
Summit Welcome
Robert W. Carlson, MD
Chief Executive Officer, National Comprehensive Cancer Network

9:25 – 10:20 AM
Presentation of Conclusions and Recommendations of the Work Group
Alan Venook, MD
UCSF Helen Diller Comprehensive Cancer Center

10:25 – 10:40 AM
Break

10:45 AM – 12:15 PM
Panel Discussion - Strategies for Implementation of Clinical Trials in the Era of Small Subsets and Multiple Agents
Moderated by:
Cliff Goodman, PhD
The Lewin Group

David Flockhart, MD, PhD
Indiana University

Ramaswamy Govindan, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

William Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Amy McKee, MD
Food and Drug Administration

Eric Slosberg, PhD
Novartis

Alan Venook, MD
UCSF Helen Diller Comprehensive Cancer Center

12:20 – 1:20 PM  
Lunch

1:25 – 2:55 PM        
Panel Discussion - Identifying and Defining Standards of Care for Cancer Subtypes
Moderated by:
Cliff Goodman, PhD
The Lewin Group

Michael Deininger, MD
Huntsman Cancer Institute at the University of Utah

David Flockhart, MD, PhD
Indiana University

Ramaswamy Govindan, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

William Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Rosemarie Hakim, PhD
Centers for Medicare & Medicaid Services

Jennifer Malin, MD, PhD
WellPoint

Lisa McShane, PhD
National Cancer Institute

Asif Velani
Genentech

3:00 – 3:30 PM   
Wrap up, Conclusions, and Next Steps
Robert W. Carlson, MD
Chief Executive Officer, National Comprehensive Cancer Network

Alan Venook, MD
UCSF Helen Diller Comprehensive Cancer Center

*Subject to change.

Program Location

Bethesda Marriott
5151 Pooks Hill Road
Bethesda, Maryland 20814

Fees

Employees of NCCN Member Institutions are eligible to receive a discounted registration fee.

Government

$199

Health Care Professionals (Other)

$299

Industry

$599

NCCN Member Institution

$120

Nonprofit/Academia

$299

Patient

$199

Patient Advocate

$199

Physician

$299

Supporters

Supported by an educational donation provided by Amgen.

Supported by a charitable contribution from Bristol-Myers Squibb.

Supported by grants from Abbott Molecular; Genentech; and ImmunoGen, Inc.

Supported by Astellas Pharma, US, Inc.; Biodesix; Gilead Sciences, Inc.; Incyte Corporation; Janssen; Medivation Inc.; Millennium: The Takeda Oncology Company; Onyx Pharmaceuticals, Inc., an Amgen subsidiary; and TEVA Oncology.

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dendreon; Helsinn; Novartis Oncology; and Xcenda, an AmerisourceBergen Consulting Services company.